These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
127 related articles for article (PubMed ID: 8736239)
1. Reactogenicity and immunogenicity of a new recombinant hepatitis B vaccine containing Pre S antigens: a preliminary report. Hourvitz A; Mosseri R; Solomon A; Yehezkelli Y; Atsmon J; Danon YL; Koren R; Shouval D J Viral Hepat; 1996 Jan; 3(1):37-42. PubMed ID: 8736239 [TBL] [Abstract][Full Text] [Related]
2. Safety and immunogenicity of a new mammalian cell-derived recombinant hepatitis B vaccine containing Pre-S1 and Pre-S2 antigens in adults. Raz R; Koren R; Bass D Isr Med Assoc J; 2001 May; 3(5):328-32. PubMed ID: 11411195 [TBL] [Abstract][Full Text] [Related]
3. Comparative study of the immunogenicity and safety of two doses of recombinant hepatitis B vaccine in healthy adolescents. Schiff GM; Sherwood JR; Zeldis JB; Krause DS J Adolesc Health; 1995 Jan; 16(1):12-7. PubMed ID: 7742331 [TBL] [Abstract][Full Text] [Related]
4. Safety and immunogenicity of a novel mammalian cell-derived recombinant hepatitis B vaccine containing Pre-S1 and Pre-S2 antigens in neonates. Yerushalmi B; Raz R; Blondheim O; Shumov E; Koren R; Dagan R Pediatr Infect Dis J; 1997 Jun; 16(6):587-92. PubMed ID: 9194109 [TBL] [Abstract][Full Text] [Related]
5. Safety and immunogenicity of a novel mammalian cell-derived recombinant hepatitis B vaccine containing Pre-S1 and Pre-S2 antigens in children. Raz R; Dagan R; Gallil A; Brill G; Kassis I; Koren R Vaccine; 1996 Feb; 14(3):207-11. PubMed ID: 8920701 [TBL] [Abstract][Full Text] [Related]
6. Comparison of the immune response of four different dosages of a yeast-recombinant hepatitis B vaccine in Singapore children: a four-year follow-up study. Goh KT; Tan KL; Kong KH; Oon CJ; Chan SH Bull World Health Organ; 1992; 70(2):233-9. PubMed ID: 1600584 [TBL] [Abstract][Full Text] [Related]
7. Surface antibody and cytokine response to recombinant Chinese hamster ovary cell (CHO) hepatitis B vaccine. Zhang W; Han L; Lin C; Wang H; Pang X; Li L; Gao P; Lin H; Gong X; Tang Y; Ma J; Zhang H; Wang C; Yang P; Li H; Sun M; He X Vaccine; 2011 Aug; 29(37):6276-82. PubMed ID: 21722684 [TBL] [Abstract][Full Text] [Related]
8. [Study on the immuno-effects and influencing factors of Chinese hamster ovary (CHO) cell hepatitis B vaccine among adults, under different dosages]. Zhang W; Lin CY; Han LL; Li LQ; Gao P; Lin H; Gong XH; Huang F; Tang YQ; Ma JX; Zhang HY; Wang C; Yang P; Li H; Sun MP; He X; Pang XH Zhonghua Liu Xing Bing Xue Za Zhi; 2010 Jul; 31(7):767-70. PubMed ID: 21162840 [TBL] [Abstract][Full Text] [Related]
9. Improved immunogenicity in mice of a mammalian cell-derived recombinant hepatitis B vaccine containing pre-S1 and pre-S2 antigens as compared with conventional yeast-derived vaccines. Shouval D; Ilan Y; Adler R; Deepen R; Panet A; Even-Chen Z; Gorecki M; Gerlich WH Vaccine; 1994 Nov; 12(15):1453-9. PubMed ID: 7533967 [TBL] [Abstract][Full Text] [Related]
10. Comparative study of the immunogenicity and safety of two dosing schedules of hepatitis B vaccine in neonates. Bassily S; Kotkat A; Gray G; Hyams KC; Brown FM; Imam IZ; Arthur R Am J Trop Med Hyg; 1995 Oct; 53(4):419-22. PubMed ID: 7485697 [TBL] [Abstract][Full Text] [Related]
11. Immunogenicity of a 'pre-S2 plus S' hepatitis B vaccine in healthy adults. Katkov WN; Watkins E; DeMelia HC; Dienstag JL J Viral Hepat; 1994; 1(1):79-83. PubMed ID: 8790563 [TBL] [Abstract][Full Text] [Related]
13. Recombinant DNA hepatitis B vaccine containing Pre-S components of the HBV coat protein--a preliminary study on immunogenicity. Yap I; Guan R; Chan SH Vaccine; 1992; 10(7):439-42. PubMed ID: 1535170 [TBL] [Abstract][Full Text] [Related]
14. A comparative trial of two surface subunit recombinant hepatitis B vaccines vs a surface and PreS subunit vaccine for immunization of healthy adults. Eyigün CP; Yilmaz S; Gül C; Sengül A; Hacibektasoglu A; Van Thiel DH J Viral Hepat; 1998 Jul; 5(4):265-9. PubMed ID: 9751013 [TBL] [Abstract][Full Text] [Related]
15. Immune persistence 17 to 20 years after primary vaccination with recombination hepatitis B vaccine (CHO) and the effect of booster dose vaccination. Zhao YL; Han BH; Zhang XJ; Pan LL; Zhou HS; Gao Z; Hao ZY; Wu ZW; Ma TL; Wang F; Li Q; Bi SL; Ma JC BMC Infect Dis; 2019 May; 19(1):482. PubMed ID: 31146699 [TBL] [Abstract][Full Text] [Related]
16. Comparison of two immunization schedules with recombinant hepatitis B vaccine and natural immunity acquired by hepatitis B infection in dialysis patients. el-Reshaid K; al-Mufti S; Johny KV; Sugathan TN Vaccine; 1994; 12(3):223-34. PubMed ID: 8165854 [TBL] [Abstract][Full Text] [Related]
17. The safety and immunogenicity of a recombinant hepatitis B vaccine in neonates. Gunn TR; Bosley A; Woodfield DG N Z Med J; 1989 Jan; 102(860):1-3. PubMed ID: 2521527 [TBL] [Abstract][Full Text] [Related]
18. Evaluation of the immunogenicity of a recombinant vaccine against hepatitis B containing S and pre-S2 sequences using two different schedules. Gizaris V; Roumeliotou A; Ktenas E; Papoutsakis G; Papaevangelou G Vaccine; 1993 Nov; 11(14):1445-7. PubMed ID: 8310765 [TBL] [Abstract][Full Text] [Related]
19. A new pre-S containing recombinant hepatitis B vaccine and its effect on non-responders: a preliminary observation. Yap I; Chan SH Ann Acad Med Singap; 1996 Jan; 25(1):120-2. PubMed ID: 8779530 [TBL] [Abstract][Full Text] [Related]
20. MF59 adjuvant enhances the antibody response to recombinant hepatitis B surface antigen vaccine in primates. Traquina P; Morandi M; Contorni M; Van Nest G J Infect Dis; 1996 Dec; 174(6):1168-75. PubMed ID: 8940205 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]